Helicobacter pylori and its effects on human health and disease

Archives of Iranian Medicine

Volumn 14, Issue 3, 2011, Pages 192-199

  Kamangar, Farin ^a,b   Sheikhattari, Payam ^a   Mohebtash, Mahsa ^c  

^a MORGAN STATE UNIVERSITY   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNION MEMORIAL HOSPITAL   (United States)

Author keywords

Anemia; Atherosclerosis; Esophageal cancer; Gastric cancer; Helicobacter pylori

Indexed keywords

ACHLORHYDRIA; ASTHMA; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; DIGESTIVE TRACT ENDOSCOPY; DISEASE ASSOCIATION; DUODENUM ULCER; DYSPEPSIA; ESOPHAGUS CANCER; FUNCTIONAL DYSPEPSIA; GASTRITIS; GASTROESOPHAGEAL REFLUX; GENETIC VARIABILITY; HELICOBACTER PYLORI; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION RISK; IRON DEFICIENCY ANEMIA; MICROBIOLOGY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONCARDIAC GASTRIC CANCER; NONHUMAN; PEPTIC ULCER; PREVALENCE; REVIEW; STOMACH ACID SECRETION; STOMACH EPITHELIUM; STOMACH LYMPHOMA; STOMACH PH; STOMACH ULCER; ADENOCARCINOMA; ANEMIA, IRON-DEFICIENCY; CARCINOMA, SQUAMOUS CELL; CARDIOVASCULAR DISEASES; ESOPHAGEAL NEOPLASMS; HELICOBACTER INFECTIONS; LYMPHOMA, B-CELL, MARGINAL ZONE; PROTECTION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTOR; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANEMIA, IRON-DEFICIENCY; ASTHMA; CARCINOMA, SQUAMOUS CELL; CARDIOVASCULAR DISEASES; DYSPEPSIA; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; PEPTIC ULCER; PROTECTIVE FACTORS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS; STOMACH NEOPLASMS;

EID: 79961181521     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Peek RM Jr., Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002; 2: 28-37. (Pubitemid 37328805)
2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1: 1311-1315.
3. Lam SK. Pathogenesis and pathophysiology of duodenal ulcer. Clin Gastroenterol. 1984; 13: 447-472. (Pubitemid 14051994)
4. Massarrat S. Georg Ernst Konjetzny, German surgeon of the 20th century: a great pioneer who suggested the bacterial genesis of gastritis and its relationship to peptic ulcer and gastric cancer. Am J Gastroenterol. 2003; 98: 1899-1900. (Pubitemid 36959182)
5. Schwartz K. Ueber Penetrierdende magen- und jejunal geswurw. Breitr Klin Chir. 1919; 96: 100.
6. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis. 1993; 168: 219-221. (Pubitemid 23178754)
7. Malaty HM, El-Kasabany A, Graham DY, Miller CC, Reddy SG, Srinivasan SR, et al. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet. 2002; 359: 931-935. (Pubitemid 34246383)
8. Torres J, Leal-Herrera Y, Perez-Perez G, Gomez A, Camorlinga-Ponce M, Cedillo-Rivera R, et al. A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis. 1998; 178: 1089-1094. (Pubitemid 28452203)
9. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000; 22: 283-297. (Pubitemid 32116099)
10. Nouraie M, Latifi-Navid S, Rezvan H, Radmard AR, Maghsudlu M, Zaer-Rezaii H, et al. Childhood hygienic practice and family education status determine the prevalence of Helicobacter pylori infection in Iran. Helicobacter. 2009; 14: 40-46.
11. O'Connor A, Gisbert J, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter. 2009; 14 (suppl 1): 46-51.
12. Lind T, Veldhuyzen van ZS, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996; 1: 138-144. (Pubitemid 126671139)
13. Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999; 116: 248-253. (Pubitemid 29055345)
14. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology. 2008; 135: 787-795.
15. Lunet N, Barros H. Helicobacter pylori infection and gastric cancer: facing the enigmas. Int J Cancer. 2003; 106: 953-960. (Pubitemid 37071677)
16. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995; 9 (suppl 2): 33-39.
17. Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature. 2007; 445: 915-918.
18. Falush D, Wirth T, Linz B, Pritchard JK, Stephens M, Kidd M, et al. Traces of human migrations in Helicobacter pylori populations. Science. 2003; 299: 1582-1585. (Pubitemid 36297709)
19. Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep. 2006; 7: 956-960. (Pubitemid 44480504)
20. Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis. 2000; 181: 1359-1363. (Pubitemid 30252540)
21. Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis. 2008; 198: 553-560.
22. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992; 102: 760-766.
23. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004; 4: 688-694. (Pubitemid 39215067)
24. Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest. 2001; 107: 767-773. (Pubitemid 32274024)
25. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 1985; 142: 436-439. (Pubitemid 15233564)
26. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol. 1987; 82: 192-199. (Pubitemid 17047002)
27. Ramsey EJ, Carey KV, Peterson WL, Jackson JJ, Murphy FK, Read NW, et al. Epidemic gastritis with hypochlorhydria. Gastroenterology. 1979; 76: 1449-1457. (Pubitemid 9183097)
28. Gledhill T, Leicester RJ, Addis B, Lightfoot N, Barnard J, Viney N, et al. Epidemic hypochlorhydria. Br Med J (Clin Res Ed). 1985; 290: 1383-1386. (Pubitemid 15122694)
29. Graham DY, Alpert LC, Smith JL, Yoshimura HH. Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. Am J Gastroenterol. 1988; 83: 974-980.
30. Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology. 1990; 99: 1315-1323. (Pubitemid 20381865)
31. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology. 1998; 115: 642-648. (Pubitemid 28397299)
32. Bartlett JG. Campylobacter pylori: fact or fancy? Gastroenterology. 1988; 94: 229-232.
33. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002; 359: 14-22. (Pubitemid 34119190)
34. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006; (2): CD003840.
35. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998; 339: 1869-1874. (Pubitemid 29013929)
36. Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999; 341: 1106-1111. (Pubitemid 29466222)
37. Blum AL, Talley NJ, O'Morain C, van Zanten SV, Labenz J, Stolte M, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med. 1998; 339: 1875-1881.
38. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2005; CD002096.
39. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005; 129: 1753-1755.
40. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 2005; 129: 1756-1780. (Pubitemid 41597412)
41. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003; 326: 737.
42. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, et al. Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter. 2008; 13: 352-360.
43. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. 1994.
44. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998; 114: 1169-1179. (Pubitemid 28243902)
45. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999; 94: 2373-2379. (Pubitemid 29420659)
46. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther. 1999; 13: 851-856. (Pubitemid 29312768)
47. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001; 49: 347-353.
48. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006; 98: 1445-1452. (Pubitemid 44605589)
49. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345: 784-789.
50. Forman D. Helicobacter pylori: the gastric cancer problem. Gut. 1998; 43 (suppl 1): S33-S34. (Pubitemid 28338109)
51. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009; 151: 121-128.
52. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of meta-chronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372: 392-397.
53. Dawsey SM, Mark SD, Taylor PR, Limburg PJ. Gastric cancer and H. pylori. Gut. 2002; 51: 457-458.
54. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003; 125: 1636-1644. (Pubitemid 37500427)
55. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338: 1175-1176.
56. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 330: 1267-1271. (Pubitemid 24129959)
57. Eck M, Schmausser B, Haas R, Greiner A, Czub S, Muller-Hermelink HK. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology. 1997; 112: 1482-1486. (Pubitemid 27181371)
58. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de BM, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342: 575-577. (Pubitemid 23259233)
59. Roggero E, Zucca E, Pinotti G, Pascarella A, Capella C, Savio A, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med. 1995; 122: 767-769.
60. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999; 131: 88-95.
61. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long-term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004; 53: 34-37. (Pubitemid 38083007)
62. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk - A meta-analysis. Cancer Prev Res. 2008; 1: 329-338.
63. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007; 5: 1413-1417.
64. Zhuo X, Zhang Y, Wang Y, Zhuo W, Zhu Y, Zhang X. Helicobacter pylori infection and oesophageal cancer risk: association studies via evidence-based meta-analyses. Clin Oncol (R Coll Radiol). 2008.
65. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998; 58: 588-590. (Pubitemid 28099460)
66. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology. 2007; 132: 2116-2130. (Pubitemid 46693747)
67. Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut. 2007; 57: 173-180.
68. Dufour C, Brisigotti M, Fabretti G, Luxardo P, Mori PG, Barabino A. Helicobacter pylori gastric infection and sideropenic refractory anemia. J Pediatr Gastroenterol Nutr. 1993; 17: 225-227. (Pubitemid 23249808)
69. Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G, et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med. 1999; 131: 668-672. (Pubitemid 29517952)
70. Milman N, Rosenstock S, Andersen L, Jorgensen T, Bonnevie O. Serum ferritin, hemoglobin, and Helicobacter pylori infection: a seroepidemiologic survey comprising 2794 Danish adults. Gastroenterology. 1998; 115: 268-274. (Pubitemid 28363418)
71. Peach HG, Bath NE, Farish SJ. Helicobacter pylori infection: an added stressor on iron status of women in the community. Med J Aust. 1998; 169: 188-190. (Pubitemid 28408370)
72. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter. 2008; 13: 323-340.
73. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56: 772-781.
74. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998; 352: 878.
75. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009; 113: 1231-1240.
76. Anderson HR. Prevalence of asthma. BMJ. 2005; 330: 1037-1038. (Pubitemid 40646549)
77. Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax. 2000; 55 (suppl 1): S2-S10.
78. Matricardi PM, Rosmini F, Riondino S, Fortini M, Ferrigno L, Rapicetta M, et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ. 2000; 320: 412-417.
79. Linneberg A, Ostergaard C, Tvede M, Andersen LP, Nielsen NH, Madsen F, et al. IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. J Allergy Clin Immunol. 2003; 111: 847-853. (Pubitemid 36470259)
80. Thjodleifsson B, Asbjomsdottir H, Sigurjonsdottir RB, Gislason D, Olafsson I, Cook E, et al. Seroprevalence of Helicobacter pylori and cagA antibodies in Iceland, Estonia, and Sweden. Scand J Infect Dis. 2007; 39: 683-689. (Pubitemid 47180469)
81. Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med. 2007; 167: 821-827. (Pubitemid 46658341)
82. Reibman J, Marmor M, Filner J, Fernandez-Beros ME, Rogers L, Perez-Perez GI, et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS One. 2008; 3: e4060.
83. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-843. (Pubitemid 30165206)
84. Ridker PM, Danesh J, Youngman L, Collins R, Stampfer MJ, Peto R, et al. A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men. Ann Intern Med. 2001; 135: 184-188. (Pubitemid 32738312)
85. Pasceri V, Patti G, Cammarota G, Pristipino C, Richichi G, Di SG. Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am Heart J. 2006; 151: 1215-1222.
86. Zhang S, Guo Y, Ma Y, Teng Y. Cytotoxin-associated gene-A-sero-positive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chin Med J (Engl). 2008; 121: 946-951.
87. Franceschi F, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, et al. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis. 2009; 202: 535-542.
88. Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G, et al. Association between Helicobacter pylori infection and pancreatic cancer. Oncology. 1998; 55: 16-19.
89. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst. 2001; 93: 937-941. (Pubitemid 32624651)
90. Limburg PJ, Stolzenberg-Solomon RZ, Colbert LH, Perez-Perez GI, Blaser MJ, Taylor PR, et al. Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers. Cancer Epidemiol Biomarkers Prev. 2002; 11: 1095-1099. (Pubitemid 35192663)
91. Shmuely H, Passaro D, Figer A, Niv Y, Pitlik S, Samra Z, et al. Relationship between Helicobacter pylori CagA status and colorectal cancer. Am J Gastroenterol. 2001; 96: 3406-3410. (Pubitemid 34016668)
92. Wagtmans MJ, Witte AM, Taylor DR, Biemond I, Veenendaal RA, Verspaget HW, et al. Low seroprevalence of Helicobacter pylori antibodies in historical sera of patients with Crohn's disease. Scand J Gastroenterol. 1997; 32: 712-718. (Pubitemid 27334483)
93. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol. 2009; 19: 431-444.
94. Franceschi F, Gasbarrini A. Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol. 2007; 21: 325-334. (Pubitemid 46421908)
95. Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter. 2009; 14 (suppl 1): 58-68.
96. Weigt J, Malfertheiner P. Influence of Helicobacter pylori on gastric regulation of food intake. Curr Opin Clin Nutr Metab Care. 2009; 12: 522-525.
97. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS. Plasma ghrelin following cure of Helicobacter pylori. Gut. 2003; 52: 637-640. (Pubitemid 36528862)
98. Perez-Perez GI, Salomaa A, Kosunen TU, Daverman B, Rautelin H, Aromaa A, et al. Evidence that cagA(+) Helicobacter pylori strains are disappearing more rapidly than cagA(-) strains. Gut. 2002; 50: 295-298. (Pubitemid 34161041)
99. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150. (Pubitemid 46655601)
100. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83: 2049-2053.
101. Powell J, McConkey CC, Gillison EW, Spychal RT Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer. 2002; 102: 422-427. (Pubitemid 35265884)
102. Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, et al. Epidemiologic features of upper gastrointestinal tract cancer in northeastern Iran. Br J Cancer. 2004; 90: 1402-1406. (Pubitemid 38586269)
103. Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005; 113: 456-463. (Pubitemid 40038715)
104. Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut. 2008; 57: 561-567.
105. Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res. 2008; 1: 308-311.
106. Blaser MJ. An endangered species in the stomach. Sci Am. 2005; 292: 38-45. (Pubitemid 40182990)
107. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol. 2009; 7: 887-894.
108. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastroduodenal diseases. Annu Rev Pathol. 2006; 1: 63-96.
109. Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh HM, et al. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology. 2007; 133: 926-936. (Pubitemid 47374139)
110. Matsukura N, Yokomuro S, Yamada S, Tajiri T, Sundo T, Hadama T, et al. Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. Jpn J Cancer Res. 2002; 93: 842-847.
111. Hamada T, Yokota K, Ayada K, Hirai K, Kamada T, Haruma K, et al. Detection of Helicobacter hepaticus in human bile samples of patients with biliary disease. Helicobacter. 2009; 14: 545-551.
112. Crick F. What Mad Pursuit: A Personal View of Scientific Discovery. New York, NY, USA: Basic Books; 1990.